Impact of tenofovir vs. entecavir treatment on progression of chronic hepatitis B: A nationwide cohort study [PDF]
JHEP ReportsBackground & Aims: Conflicting evidence exists on hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B (CHB) receiving tenofovir vs. entecavir.
Wan-Jung Wu +6 more
doaj +2 more sources
Comparative analysis of tenofovir alafenamide and entecavir on renal function and serum lipids in liver transplant recipients: a controlled retrospective cohort study [PDF]
BMC GastroenterologyBackground Antiviral treatments can impact serum lipids as well as kidney function. We conducted a retrospective observational study with a 48-month follow-up period, involving liver transplant recipients receiving either entecavir or tenofovir ...
Hüseyin Döngelli +7 more
doaj +2 more sources
Comparative Efficacy and Renal Safety of Entecavir and Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B: A Retrospective Cohort Study From Vietnam [PDF]
Pharmacology Research & PerspectivesTenofovir disoproxil fumarate (TDF) and entecavir (ETV) are first‐line antiviral agents for chronic hepatitis B (CHB), yet comparative real‐world data in Southeast Asian populations remain limited.
Thong Duy Vo +2 more
doaj +2 more sources
Genetic Evidence for Genotoxic Effect of Entecavir, an Anti-Hepatitis B Virus Nucleotide Analog. [PDF]
PLoS ONE, 2016 Nucleoside analogues (NAs) have been the most frequently used treatment option for chronic hepatitis B patients. However, they may have genotoxic potentials due to their interference with nucleic acid metabolism.
Lei Jiang +6 more
doaj +1 more source
Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B [PDF]
Clinical and Molecular Hepatology, 2013 Background/AimsMolecular diagnostic methods have enabled the rapid diagnosis of drug-resistant mutations in hepatitis B virus (HBV) and have reduced both unnecessary therapeutic interventions and medical costs.
Sang Hoon Ahn +7 more
doaj +1 more source
The Korean Journal of Gastroenterology, 2021 Background/Aims: Clinical equivalence of generic antiviral agents for chronic hepatitis B (CHB) has not been demonstrated, particularly in cases with previous antiviral resistance. Entecavir 1 mg is prescribed frequently as a mono- or combination therapy
Young Eun Ahn +4 more
doaj +1 more source
Entecavir as a P2X7R antagonist ameliorates platelet activation and thrombus formation
Journal of Pharmacological Sciences, 2020 Platelet activation is the primary cause of thrombosis. The P2X7 receptor (P2X7R) is a therapeutic target of thrombosis. However, it is still unknown whether P2X7R activation affects platelet thrombus.
Yue Ming +13 more
doaj +1 more source
BMC Cancer, 2023 Background At present, there are a variety of antiviral drugs for HBV in clinical practice, but there is no standard scheme for transcatheter arterial chemoembolization(TACE) combined with antiviral drugs. The aim of this study was to investigate whether
Haohao Lu +3 more
doaj +1 more source
Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
Biomedicines, 2023 Chronic hepatitis B (CHB) relapse occurs after the cessation of nucleos(t)ide analogues (NUC) therapy due to the waning of viral suppression. Few studies have investigated the viral relapse rate and clinical relapse rate after tenofovir alafenamide (TAF)
Chih-Wen Huang +5 more
doaj +1 more source
Journal of Family Medicine and Primary Care, 2021 Introduction: The aim of the study was to compare the safety and efficacy of tenofovir versus entecavir for treatment of naive acute on chronic liver failure (ACLF) due to hepatitis B virus (HBV) (ACLF-B).
Sharker M. S. Hossain +8 more
doaj +1 more source